文献速递骨软组织肉瘤与黑色素瘤

地中海饮食与晚期黑色素瘤免疫检查点阻断治疗结局的关联

Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma.
PubMed 文献 · JAMA Oncol · 2023-01-01

这项多中心队列研究(PRIMM研究)纳入荷兰和英国91例接受免疫检查点阻断(ICB)的晚期黑色素瘤患者,通过食物频率问卷评估治疗前饮食习惯。逻辑广义相加模型显示,富含全谷物、鱼、坚果、水果和蔬菜的地中海饮食模式与总体缓解率(ORR)和12个月无进展生存(PFS-12)概率呈正线性关联。作者认为需要不同地区的大样本前瞻性研究来证实这些发现。

要点

  • 地中海饮食模式与ICB治疗的ORR概率呈正线性关联(P=0.02)。
  • 地中海饮食模式与PFS-12概率呈正线性关联(P=0.01)。
  • 作者指出需不同地区的大样本前瞻性研究证实上述发现。

核心结论

  • 这项队列研究发现,被广泛推荐的健康饮食模式地中海饮食与ICB治疗反应之间存在正相关。
  • 需要不同地区的大样本前瞻性研究来证实这些发现,并进一步阐明饮食在ICB治疗中的作用。

研究设计与样本

  • 这项多中心队列研究(PRIMM研究)在荷兰和英国的癌症中心开展,纳入91例未接受过ICB、于2018年至2021年间接受ICB治疗的晚期黑色素瘤患者。
  • 患者接受抗程序性细胞死亡蛋白1和抗细胞毒性T淋巴细胞相关抗原4单药或联合治疗。
  • 治疗前通过食物频率问卷评估膳食摄入。
  • 荷兰参与者44例(平均[标准差]年龄59.43[12.74]岁;女性22例[50%]);英国参与者47例(平均[标准差]年龄66.21[16.63]岁;女性15例[32%])。
  • 膳食与临床数据来自2018年至2021年间在英国和荷兰接受ICB治疗的91例晚期黑色素瘤患者,为前瞻性收集。

主要发现

  • 逻辑广义相加模型显示,富含全谷物、鱼、坚果、水果和蔬菜的地中海饮食模式与ORR概率呈正线性关联(ORR概率0.77;P=0.02;错误发现率0.032;有效自由度0.83)。
  • 该饮食模式与PFS-12概率呈正线性关联(PFS-12概率0.74;P=0.01;错误发现率0.021;有效自由度1.54)。

关键数值与推荐

  • 主要终点为总体缓解率(ORR)、12个月无进展生存(PFS-12)和≥2级免疫相关不良事件。
  • 地中海饮食模式与ORR概率正线性关联:ORR概率0.77;P=0.02;错误发现率0.032;有效自由度0.83。
  • 地中海饮食模式与PFS-12概率正线性关联:PFS-12概率0.74;P=0.01;错误发现率0.021;有效自由度1.54。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要不同地区的大样本前瞻性研究来证实这些发现,并进一步阐明饮食在ICB治疗中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Immune checkpoint blockade (ICB) has improved the survival of patients with advanced melanoma. Durable responses are observed for 40% to 60% of patients, depending on treatment regimens. However, there is still large variability in the response to treatment with ICB, and patients experience a range of immune-related adverse events of differing severity. Nutrition, through its association with the immune system and gut microbiome, is a poorly explored but appealing target with potential to improve the efficacy and tolerability of ICB. OBJECTIVE: To investigate the association between habitual diet and response to treatment with ICB. DESIGN, SETTING, AND PARTICIPANTS: This multicenter cohort study (the PRIMM study) was conducted in cancer centers in the Netherlands and UK and included 91 ICB-naive patients with advanced melanoma who were receiving ICB between 2018 and 2021. EXPOSURES: Patients were treated with anti-programmed cell death 1 and anti-cytotoxic T lymphocyte-associated antigen 4 monotherapy or combination therapy. Dietary intake was assessed through food frequency questionnaires before treatment. MAIN OUTCOMES AND MEASURES: Clinical end points were defined as overall response rate (ORR), progression-free survival at 12 months (PFS-12), and immune-related adverse events that were grade 2 or higher. RESULTS: There were a total of 44 Dutch participants (mean [SD] age, 59.43 [12.74] years; 22 women [50%]) and 47 British participants (mean [SD] age, 66.21 [16.63] years; 15 women [32%]). Dietary and clinical data were prospectively collected from 91 patients receiving ICB between 2018 and 2021 for advanced melanoma in the UK and the Netherlands. Logistic generalized additive models revealed positive linear associations between a Mediterranean dietary pattern that was high in whole grains, fish, nuts, fruit, and vegetables and the probability of ORR and PFS-12 (probability of 0.77 for ORR; P = .02; false discovery rate, 0.032; effective degrees of freedom, 0.83; probability of 0.74 for PFS-12; P = .01; false discovery rate, 0.021; effective degrees of freedom, 1.54). CONCLUSIONS AND RELEVANCE: This cohort study found a positive association between a Mediterranean diet, a widely recommended model of healthy eating, and response to treatment with ICB. Large prospective studies from different geographies are needed to confirm the findings and further elucidate the role of diet in the context of ICB.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Bolte LA, Lee KA, Björk JR, et al. Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma. JAMA Oncol. 2023. PMID: 36795408. doi:10.1001/jamaoncol.2022.7753

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。